European Medicines Agency says number of blood clots in vaccinated people ‘seems not to be higher than that seen in the general population’
- France seeks swift safety verdict on AstraZeneca vaccine
- Benefits of Oxford/AstraZeneca vaccine outweigh any risk, says EMA
- Europe’s caution over Oxford vaccine about more than the science
- Which European states have paused AstraZeneca jabs?
- Olympic torch relay legs could be cancelled if rules broken
Cooke defends the authorisation of the AstraZeneca shot.
We had very large clinical data sets that showed safety and efficacy in large populations. [For the AstraZeneca jab] We had efficacy in 18,000 patients, safety is 30,000 patients. We remain convinced the benefits outweigh the risks.
Some background reading:
Related: Europe’s caution over Oxford vaccine about more than the science
Continue reading…
